Current Report Filing (8-k)
March 01 2017 - 9:08AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 1, 2017
Commission File Number: 0-24260
Amedisys, Inc.
(Exact name of registrant as specified in charter)
|
|
|
|
|
Delaware
|
|
11-3131700
|
|
(State or other jurisdiction
of incorporation)
|
|
(IRS Employer
Identification No.)
|
|
|
3854 American Way, Suite A, Baton Rouge, LA 70816
(Address of principal executive offices, including zip code)
(225) 292-2031 or (800) 467-2662
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (
see
General Instruction A.2 below):
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
Item 7.01.
|
Regulation FD Disclosure.
|
On March 1, 2017, Amedisys, Inc. (the
“Company”) issued a press release announcing that it has signed a definitive agreement to acquire Tenet Healthcare’s home health and hospice operations in Arizona, Illinois, Massachusetts, and Texas, a copy of which is furnished
herewith as Exhibit 99.1 to this Current Report on Form 8-K.
The information included in this Current Report on Form 8-K under this
Item 7.01 (including Exhibit 99.1 hereto) is being “furnished” and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or
otherwise subject to the liabilities of Section 18, nor shall it be incorporated by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such
filing. The information included in this Current Report on Form 8-K under this Item 7.01 (including Exhibit 99.1 hereto) will not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the
requirements of Regulation FD.
|
Item 9.01.
|
Financial Statements and Exhibits.
|
|
|
|
|
|
Exhibit
Number
|
|
Description
|
|
|
|
|
99.1
|
|
Press Release dated March 1, 2017
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
AMEDISYS, INC.
|
|
|
|
|
By:
|
|
/s/ Paul B. Kusserow
|
|
Paul B. Kusserow
President and
Chief Executive Officer
|
|
|
|
DATE: March 1, 2017
|
EXHIBIT INDEX
|
|
|
|
|
Exhibit
Number
|
|
Description
|
|
|
|
|
99.1
|
|
Press Release dated March 1, 2017
|
Amedisys (NASDAQ:AMED)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amedisys (NASDAQ:AMED)
Historical Stock Chart
From Apr 2023 to Apr 2024
